© 1996, 1997, 2001 by Galen Daryl Knight and VitaleTherapeutics, Inc.
Effects of Tumor Burden upon Therapeutic Response to the Vitaletheine Modulators
Dead tumor cells place additional discriminatory burdens upon already challenged
immune responses to tumor since the immune system must distinguish between
live and dead tumor cells and focus upon the former for a successful response.
The following results demonstrate that this is an oversimplification. Therapeutic
responses to vitalethine are largely attenuated by dead tumor cell burden
while those to the benzyl derivative are not appreciably affected. It is
theorized that dead tumor cell ghosts produce
lipid epoxides that are more likely to react with the vitaletheine
(generated from vitalethine) than with the sulfenic
acids produced from the benzyl derivative.